The Food and Drug Administration is discussing whether unapproved peptides should be allowed in certain compounded prescription drugs. What are they?

A FDA advisory committee will review evidence surrounding peptides. Experts are concerned there is a paucity of evidence to back their approval for legal compounding.

The FDA could decide whether to loosen rules around peptide production this week. Some telehealth players are already seeing dollar signs.